Mesna
NK/T-cell Lymphoma
Antengene CorporationSmall moleculePhase 4 / ApprovedDormant
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the NK/T-cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rivoceranib Peking University | Phase 2 | CCC |
Eloxatin Antengene Corporation | Phase 1/2 | CCC |
Anti-Cd30-Car-Transduced T Cells Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 | CC |
Atg-010 Antengene Corporation | Phase 1/2 | CC |
Ebv Tcr-T Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Early Phase 1 | C |
Same molecule, other indications
Mesna is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →